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Summary.- The relationship of serum carcinoembryonic antigen (CEA) levels to
tumour size and antigen content was studied in artificially immune-deprived mice
bearing human colonic, breast and lung tumour xenografts. Size was measured as
in vivo volume and tumour weight at post-mortem. A multiple implant technique
combined with early harvest was used to minimize centrilobular tumour necrosis.
CEA was extracted from resected tumours with perchloric acid. Aradioimmunoassay
using chemical precipitation was used to estimate CEA in blood samples. A corre-
lation was found between CEA blood levels and tumour size in half the tumour lines,
in contrast to a recent report (Lewis & Keep, 1981). The CEA content was found to be
constant for one tumour line but not another. The possibility that central necrosis in
xenograft tumours may account for the discrepancies is discussed. There may be
serious limitations for the use of xenograft tumour models for studying the biology
of CEA.
CARCINOEMBRYONIC ANTIGEN (CEA)
(Gold & Freedman, 1965) remains one of
the most useful tumour-associated sub-
stances to monitor malignant disease.
Unfortunately, its assay in the blood
provides only a crude guide to tumour
behaviour; there are two main reasons
for this. First, CEA is a heterogeneous
large glycoprotein which is difficult to
define in precise chemical and immuno-
logical terms with many of the available
reagents. Second, regulation of CEA
levels in cancer patients is subject to
numerous poorly understood biological
variables with respect to its production
and release by tumours, and the mode by
which the host metabolizes and clears it
from the circulation.
Of fundamental importance to the
clinical application of anv marker is its
ability to provide a reliable index of
tumour mass. Unfortunately, CEA may
have certain failings in this respect. It is
true that there is usually an increase in
CEA in individual patients as disease
advances (Steward et al., 1974; Di Saia
ct al., 1975; Khoo & Mackay, 1976; Cove
et al., 1979; Dent & McCullough, 1980
and that many patients with advanced
malignancies are likely to have high levels
of CEA (Chu & Nemoto, 1973; Steward
et al., 1974; Barrelet & Mach, 1975;
Vincent et al., 1975; Khoo & Mackay,
1976; Di Saia et al., 1977; Borthwick
et al., 1977; Martin et al., 1977; Waalkes
et al., 1980; Wanebo 1980) which may
correlate with the stage of the disease
(Martin et al., 1977; Cove et al., 1979;
Khoo et al., 1979; Khoo & Mackay ,1976;
Gropp et al., 1980; Joyce et al., 1980) but
there are wide discrepancies in all series,
which are difficult to explain. Thus, there
appears to be a need for more precise
information on the subject. Unfortunately
the inherent variability of clinical studies
militates against uniformity, but an
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experimental study under laboratory con-
ditions could have distinct advantages.
An investigation is now described, using
a model tumour system consisting of
immune-deprived mice bearing human
CEA-producing tumours.
MATERIALS AND METHODS
Human tumours.-Human tumours already
established in transplant passage to immune-
deprived mice were screened for their CEA
content and ability to produce high titres of
CEA in the blood ofhost mice. Four colorectal
(HK1, 6, 7, 9), one breast (S32) and one
lung (p246) were selected for use. The num-
ber of previous passages ranged from 7 to 16.
Plasma CEA levels ranged from 40 to 306 ng/
ml. The histological characteristics of the
primary tumours were retained in the
xenografts, except that stroma was much
reduced and predominantly of mouse origin,
as is well described by Warenius (1979).
The karyotypes were in all cases human;
only occasional murine chromosomes being
encountered. There was a considerable
range of modal number, from 40 to 80
chromosomes.
Immune-deprived inice.-CBA/LAC mice
were used throughout. Preparation involved
thymectomy at 4-6 weeks of age, and 3
weeks later, whole-body irradiation (9 Gy at
60 cGy/min; 200 kV X-ray machine) fol-
lowed by reconstitution within 2 h by an
i.v. injection of 5 x 106 syngeneic marrow
cells (Miller et al., 1963). The mice were
suitable for xenografting from 14 days after
irradiation and reconstitution.
Grafting techniques.-Under ether general
anaesthesia, 2mm3 fragments of tumour
were placed into subcutaneous sites in each
flank through a single dorsal incision. When
it was necessary to vary the bulk of tumour
carried by individual mice, multiple implant
sites were used, 4 dorsal and 2 ventral,
through separate incisions.
Tumour measurements.-Tumour bulk was
assessed as volume in most studies. When
multiple implants were made, tumours often
coalesced, making volume measurement im-
possible. These tumours were excised at post-
mortem and weighed. Volumes were measured
as 7TD3/6, D being the mean oftwo diameters
at right angles (Nowak et al., 1978). This
assumes that the tumour is approximately
spherical. Tumours which failed to retain a
spherical or slightly elipsoidal shape were
therefore excluded. Measurement of depth
diameter was omitted because it is subject to
greater experimental error (Dethlefsen et al.,
1968). The accuracy of this formula was
checked from a calibration curve of volume
measurements against the weight of tumour
obtained after excision; this indicated a slight
tendency to over-estimate actual tumour
volume, in part due to the thickness of the
skin. No attempt was made to correct for this
because the relative values were unlikely to
be significantly in error.
Collection of blood samples.-Individual
blood samples were usually collected by
venesection via the infra-orbital sinus.
When mice were to be killed cardiac
puncture was used. Fine glass pipettes coated
with 360 ,ug tripotassium EDTA were used
and -200 a1l withdrawn each time. Plasma
was separated and stored at - 70°C until
assayed.
CEA assay.-For a number of reasons it
was necessary to devise a radioimmunoassay
especially for this study. Only small volumes
of blood could be removed from mice without
risk of serious hypovolaemia. The automated
assay in clinical use required large plasma
samples. Since with the available equipment,
samples of 50 1A were found to be the mini-
mum before unacceptable errors from the
manual pipetting manoeuvres occurred, most
of the mouse sample would be required for a
single assay. It was thus necessary to devise
a more sensitive assay.
Chemical precipitation for separating the
antisera-bound from free CEA was chosen,
because it is simpler and cheaper than a
double-antibody method, and because mouse
anti-CEA/CEA complexes are unlikely to
reduce the amount of antigen available for
binding in this type of assay (Stevens et al.,
1978).
The assay was set up in the conventional
way by Dr M. G. Ormerod and Miss N.
Neylon. The CEA used was isolated from
hepatic metastases of a human colonic car-
cinoma and purified to satisfy criteria des-
cribed by Westwood & Thomas (1975) and
Westwood et al. (1978). Anti-CEA sera were
raised in a rabbit by the method described
by Ormerod (1978). CEA was labelled with
1251 using chloramine T by Mr M. Capp. All
dilutions were in phosphate-buffered saline
(0-05M phosphate, 0-15M NaCl, pH 7415)
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FIG. 2. Standard curve for CEA radioimmunoassay (95oo tolerance limits).
containing 1 g/l bovine serum albumin (PEB)
Additional precipitants were 11-500 poly-
ethylene glycol (PEG) and pooled human
albumin.
A dilution curve of rabbit CEA antiserum
against 1251-CEA diluted to give about
2 x 104 ct/min/ng CEA was obtained. Doub-
ling dilutions of the antiserum in PEB were
made, beginning at 1: 400. Duplicate 50 ,ul
volumes of diluted antiserum, labelled CEA
and pooled normal mouse plasma were mixed
and incubated at 37°C overnight. Fifty ,tl
stored human albumin and 1 ml 11-5% PEG
solution were added and stored at 4°C for
30 min. The tubes were then centrifuged and
the radioactivity of the pellet estimated. A
titration curve (Fig. 1) indicated that - 9000
of the labelled 125I-CEA reacted with the
antiserum. A dilution of 1:5000 is shown to
react with 500% of the maximum amount of
125-CEA. This dilution was used throughout.
For each assay a standard curve (Fig. 2)
was carried out using 50 )ul solutions with
known amounts of unlabelled CEA, 1-0 ng
1251-labelled CEA and 1: 5000 dilution of
rabbit antiserum.
Specificity.-Ormerod (1978) has previously
reported that the rabbit antisera used in this
study do not react with these antigenic
determinants of CEA wihch are shared with
the non-specific cross-reacting antigen (CEX).
A dilution curve of a highly concentrated
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CEA-containing pooled mouse plasma sample
conformed to the standard curve, indicating
the purity of CEA produced in the mouse.
Precision.-The mean calibration with its
95% tolerance limits is shown in Fig. 2.
The precision throughout the dose range is
determined from these 95% tolerance limits
by taking half this difference divided by the
nominal dose to give the relative dose error
atthispoint. Thesedoseerrors, plotted against
dose to determine the region of minimum
error in the assay calibration curve revealed
a minimum dose error of 12.5% at 60 ng/ml.
At the extreme ranges of the assay this was
68 and78%.
Reproducibility.-Because batches of com-
pleted experiments were assayed together on
the same assay day, and because the relative
rather than absolute values of the CEA
estimations were important, the inter-assay
variation was irrelevant. Samples of known
value were included in each assay and intra-
assay variability was -10%.
Tissue CEA.-CEA was extracted from
freshly resected specimens using perchloric
acid by the method of Khoo et al. (1973).
CEA levels were measured by the double-
antibody radioimmunoassay method of
Laurence et at. (1972) which is used for
measuring plasma levels in hospital patients
at the Ludwig Institute. Although there were
obvious variations in precision at individual
CEA titres between this assay and the mouse
plasma assay described above, there were no
discernible qualitative differences.
Statistics.-The significance of the analysis
of data was calculated using Spearman's test
ofrank correlation coefficient.
RESULTS
CEA blood levels related to tumour mass
CEA rarely became detectable in the
blood of mice bearing the human tumours
until the total tumour volume reached
-06 ml. As individual tumours reached
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TABLE.-Correlation of tumour size with blood CEA level (Spearman's rank
correlation)
Tumour volume
range
(ml)
0-7-2-2
1 1-3
1-1-2.3
0*8-3
35 0 5-5
Tumour mass
range
(g)
CEA blood
levels
range
(ng/ml)
20-270
20-250
20-110
0-220
0*2-8-1 20-640
20-620
Correlation:
Tumour volume
(or mass)
vS CEA levels
0-92
0-26
0-82
0-32
0-66
0 44
0-38 NS
No. ofmice
9
20
7
r25
11
Tumour
Colon
HK1
HK6
HK7
HK9
Breast
S32
Lung
p246
p
<0-01
NS
<0*05
NS
<0 05
<0 05
I
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1 -.5 ml central necrosis set in. Trherefore
readings were usually taken 4-6 weeks
after transplantation, when most of the
tumours had grown to 05-1 -0 ml. Mice
bearing tutmours of voluime <0-5 ml, or
tumours which ere frankly necrotic,
ulcerated or infected, were discarded.
The results ofthe bilateral subcutaneous
flank volume study are summarized in the
Table, and illustrated in Fig. 3. The wide
scatter of CEA values within each tumour
group was of particular interest, and in
only half was there a correlation with
tumour volume HKI (Fig. 3) (P<O001),
HK7 (P<0-05) and 832 (P<0 05).
The greatest discrepancies were found
in HK6, where the largest tumours were
associated with the lowest plasma CEA
levels, whereas in p246 and HK9, mice
with relatively small tumour loads occa-
sionally had high levels of circulating
CEA. Among HK6, HK9 and p246, it
appeared that the highest CEA levels
occurred in mice bearing tumour burdens
in the mid range. It was considered that
some discrepancies might have occurred
because of centrilobular necrosis in the
larger ttimours. However, although post-
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mortem examination confirmed this in
certain cases, low CEA levels were found
in association with some large tumours
in which centrilobular necrosis was not
excessive.
The multiple implant study was des-
igned to minimize the effect of centri-
lobular necrosis. A much wider range
(0 5-8g) could thus also be attained. The
results again revealed a wide variation,
but an overall linear correlation (P < 0.05)
(Fig. 4). One notable discrepancy was in
a mouse carrying one ofthe largest tumour
loads, which had a particularly low plasma
level ofCEA.
The relationship of tumour CEA content,
tumour mass and CEA blood levels
HK9 and HK6 tumours were used for
this investigation. The HK9 study was
an extension of the multiple-implant
investigation described above, whereas
the HK6 multiple implants were set up
specially. (The plasma CEA estimations
for this particular group were rendered
invalid through technical fault.)
Whereas HK6 demonstrated a clear
linear correlation (P<0.05) of tumour
CEA content with tumour mass, con-
siderable disparity existed in HK9 (Fig. 5)
indicating that CEA concentration in
xenograft tumours does not remain con-
stant. The relationship of tumour CEA
content to plasma levels in HK9 was even
more disparate. The possibility had to be
considered that where there was wide
discrepancy between tumour mass and
CEA blood levels, there may have been a
corresponding discrepancy in tumour CEA
content, butthis was clearlynotthe case.
There is no indication, therefore, that
tumours with low or high concentrations
were especially associatedwith correspond-
ing plasma CEA levels.
DISCUSSION
Previous xenograft investigators have
pointed out that tumours must reach a
certain size before CEA becomes detect-
able in the blood (Primus et al., 1973;
Mach et al., 1974; Sordat et al., 1974;
Miwa et al., 1976; Lewis & Keep, 1981).
Indeed, CEA was as rare in mice bearing
small tumours in the present study that
it became policy not to measure plasma
levels until the total tumour bulk was
1'5 ml. Such a size represents 55% of
the total weight of the tumour-bearing
host, which in comparison to malignancies
in patients is enormous. In contrast,
relatively small tumours in patients are
capable of producing very high levels of
circulating CEA. This curious observation
has also been made for other markers,
such as human chorionic gonadotrophin
(hCG) (Kameya et al., 1975) and x-foeto-
protein (AFP) (Raghavan et al., 1980)
produced by xenograft tumours. The
reason cannot be wholly explained by
assay insensitivity, since small concentra-
tions should be detectable in spite of
measurement being inaccurate. It would
seem logical that CEA would only become
detectable when the amount produced
and released by the tumour exceeds
that eventually metabolized. However,
although it has been shown that CEA is
rapidly cleared by the liver in mice
(Thomas et al., 1976; Thomas & Hems,
1975) the possibility of a threshold level
for CEA clearance has not yet been
specifically investigated.
The possibility that there may be a
change in CEA synthesis during growth
should seriously be considered. Certainly,
as tumours grow centrilobular necrosis
sets in, and the CEA concentration is
naturally smaller when this becomes
extensive (Mach et al., 1974). It is not
surprising that Lewis & Keep (1981)
should find in their single tumour line that
CEA concentrations vary widely, because
their series produced tumours of vastly
differing size. The linear correlation which
was found in the HK6 tumours in the
present investigation may be because the
tumours were harvested early, before
serious centrilobular necrosis could have
occurred. The possibility that necrosis
may be an important factor affecting CEA
blood levels has been investigated by the
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author in a separate study (Quavle, 1982)
in which it was found that when necrosis
occurred rapidly and extensively, con-
siderable increases in CEA titres were
frequent. Nevertheless, the fact that the
tumour mass vs tumour CEA correlation
did not exist in HK9, in spite of similar
conditions, indicates that factors other
than necrosis are responsible.
A further anomaly identified in this
study is the finding that tumour size does
not always correlate with plasma CEA.
Again this cannot wholly be explained on
the basis of tumour necrosis because, if it
were, the correlation in the multiple-
implant study, which was harvested early,
should have been closer than in volume
studies.
Until recently, Miwa et al. (1976) were
the only workers to investigate the
relationship between blood CEA and
tumour xenograft size. Their claim for a
direct correlation does not, however,
stand up to close scrutiny, mainly because
the number of samples is small (5) and
the spread of levels and tumour size
uneven. Stragand et al. (1980) and Lewis
& Keep (1981) failed to demonstrate any
correlation in their more recent detailed
studies on a single tumour line, but the
validity of their observation should per-
haps be viewed with some circumspection
since they were using tumours which, in
some cases, were as laige as 8-8 and 7-14 g
respectively, which would be expected to
contain a considerable degree of central
necrosis. Indeed Lewis & Keep (1981)
specifically stated that "central necrosis
was a consistent feature" in their tumour
line. Since the present sudy has indicated
behavioural differences between tumour
lines, it is conceivable that the two tumour
lines used by these authors may not be
representative. A further factor, again
acknowledged by Lewis & Keep (1981),
was that their assay for CEA by a double
antibody technique may have been incap-
able of determining the presence of CEA
molecules masked by murine immuno-
globulins.
The variable ability of CEA to reflect
tumour burden is not wholly unexpected,
since a review of the extensive literature
indicates that levels of CEA in the blood
are affected by numerous other biological
variables. Even so, because the validity
of xenograft tumour models for such
investigations remains in doubt, this fail-
ing ofCEA may have been exaggerated.
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